Zenas BioPharma, Inc. Common Stock (ZBIO) Stock Price

ZBIOStock
$33.77+85.09%52W
Market Cap$2.20B
P/E
PEG Ratio
Div yield
Beta0.70

ZBIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)7.38%
Price vs S&P 500 (4W)-5.03%
VGM Score83.99

ZBIO Earnings Surprise History

Q2 25-1.25est. -1.06
Q3 25-1.22est. -0.85
Q4 25-1.39est. -1.19
Q1 26-1.46est. -1.54
Q2 26-1.77est. -0.76

ZBIO Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.36
4.36
4.36
4.36

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ZBIOZenas BioPharma, Inc. Common Stock
AA$33.77
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Zenas BioPharma, Inc. Common Stock

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on treating autoimmune diseases with obexelimab, a monoclonal antibody. The drug candidate targets B cells by binding to CD19 and FcyRIIb receptors, inhibiting their disease-driving activity while preserving cell survival—a mechanism designed to provide a differentiated treatment approach. This unique profile addresses a significant gap in autoimmune disease therapy.